Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a research note published on Friday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Down 3.1 %

LPCN stock opened at $5.27 on Friday. Lipocine has a 1 year low of $2.31 and a 1 year high of $7.15. The company has a fifty day simple moving average of $4.48 and a 200 day simple moving average of $3.47.

Lipocine (NASDAQ:LPCN) last released its earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.11. The firm had revenue of $0.22 million for the quarter. As a group, sell-side analysts forecast that Lipocine will post -1.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. lifted its position in Lipocine by 0.4% during the 1st quarter. BlackRock Inc. now owns 1,467,420 shares of the specialty pharmaceutical company’s stock worth $467,000 after acquiring an additional 6,348 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Lipocine by 146.2% during the 3rd quarter. Renaissance Technologies LLC now owns 199,400 shares of the specialty pharmaceutical company’s stock worth $90,000 after purchasing an additional 118,394 shares during the period. Millennium Management LLC bought a new position in shares of Lipocine during the 2nd quarter worth about $160,000. Goldman Sachs Group Inc. increased its holdings in shares of Lipocine by 524.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 88,615 shares of the specialty pharmaceutical company’s stock worth $121,000 after purchasing an additional 74,428 shares during the period. Finally, State Street Corp increased its holdings in shares of Lipocine by 7.5% during the 1st quarter. State Street Corp now owns 327,405 shares of the specialty pharmaceutical company’s stock worth $449,000 after purchasing an additional 22,788 shares during the period. Institutional investors and hedge funds own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.